Mymetics, Texas Biomedical continue development of HIV vaccine
Mymetics Corporation and Texas Biomedical Research Institute have announced the continuation of their partnership in developing a HIV vaccine after a previous study showed the vaccine was 87 percent effective in delaying the time of infection.
Switzerland's Mymetics' HIV-1 vaccine was developed to have the dual purpose of protecting an individual through mucosal protections and defending against infection through antibodies in the blood stream. The vaccine was tested in liquid form and is being evolved into becoming a needle-free and cold-chain independent virosomal vaccine.
Lead by Ruth Ruprecht, MD, director of the Texas Biomed AIDS Research Program, the first part of the study was based on a test on 36 primates where Mymetics' HIV vaccine was split into two phases. The first phase set out to mimic the infection of women from infected sperm at a dose 70,000 times the average dose passed on from human intercourse; the second phase increased the rate to 100,000 times the average viral dose.
Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.